THE GLOMERULUS IS the filtration unit of the kidney. Visceral glomerular epithelial cells (GEC), also known as podocytes, are critical for structural integrity as well as barrier function of the glomerulus. The importance of GEC in glomerular barrier function has been highlighted by the recent discoveries that mutations of molecules specifically expressed in GEC, such as nephrin, podocin, or ␣-actinin-4, cause severe proteinuric glomerular diseases (1, 7, 9) . Membranous nephropathy is a common cause of nephrotic syndrome in adults, and the rat model of passive Heymann nephritis (PHN) has been extensively used to study the pathophysiology of membranous nephropathy and its validity was recently discussed in detail (32) . It is known that in PHN, complement C5b-9 causes GEC injury. Activation of the complement cascade near a cell surface leads to assembly of terminal components and insertion of the C5b-9 membrane attack complex in the plasma membrane. Nucleated cells require multiple C5b-9 lesions for lysis, but, at lower doses, C5b-9 induces sublytic injury and various metabolic effects. These include activation of phospholipases [e.g., cytosolic phospholipase A 2 (cPLA 2 ), phospholipase C (2, 3)] and protein kinases [e.g., ERK, JNK (3, 17, 31) ], and induction/ activation of various other molecules [(e.g., growth factors, nuclear factor-B, and c-Jun) (31) ]. C5b-9 also causes reorganization of the actin microfilaments in cultured GEC (33) . Reorganization of the actin cytoskeleton may, in part, explain the mechanisms with which complement-mediated GEC injury leads to morphological changes and barrier dysfunction.
Mitogenic and stress-related extracellular signals are primarily transmitted intracellularly through either of the three MAPK pathways: 1) the ERK pathway, typically activated by growth factors; 2) the JNK pathway, also known as the stress-activated protein kinase pathway; and 3) the p38 pathway (14, 23) . p38 is activated by a series of cytokines, growth factors, in addition to the stress and proinflammatory signals and has important roles in stress responses, cell survival, apoptosis, and inflammation (15) . Activation of p38 involves phosphorylation of threonine and tyrosine residues in a TGY motif, resulting in increased enzyme activity. p38 lies downstream of various signaling molecules including the small G proteins Rac and Cdc42 and the protein kinase transforming growth factor-␤-activated kinase 1 (TAK1). p38 is directly activated by MAPK kinases (MKKs) MKK3 and 6. Substrates for p38 include transcription factors, such as ATF-2 or CREB, and protein kinases, such as MAPK-associated protein kinase (MAPKAPK)-2 and -3. Of interest, MAPKAPK-2, which is activated by p38, phosphorylates heat shock protein (HSP27; Ref. 5) . Although the function of HSP27 is not understood completely, it is known to associate with the actin cytoskeleton and to modulate its organization (5, 13, 22) . Overexpression of HSP27 in fibroblasts increased stress fiber stability during hyperthermia, prevented cytochalasin D-mediated actin depolymerization, and increased cortical filamentous actin, ruffling, and pinocytotic activity (11, 12) . Overexpression of non-phosphorylatable HSP27 inhibited each of these activities (11, 12) .
We reported previously that complement activates two of the MAPK pathways, namely the ERK and JNK pathways in GEC (3, 17, 31) . The JNK pathway protects GEC against complement-mediated injury (17) and also contributes to complement-mediated cyclooxygenase (COX)-2 upregulation in GEC (31) . In addition, it was recently reported that in GEC, complement-activated ERK might be important in cellular response to complement-induced DNA damage (18) . The present study addressed the role of another member of the MAPK family, p38 in GEC. We demonstrated that complement activates p38 in GEC and that p38 activation leads to cytoprotection. We also showed that HSP27 downstream of p38 may contribute to cytoprotection.
MATERIALS AND METHODS
Materials. FR-167963 was a gift from Fujisawa Pharmaceuticals (Osaka, Japan). Tissue culture media, EcdysoneInducible Mammalian Expression System, ponasterone A, hygromycin, and zeomycin were purchased from InvitrogenLife Technologies (Burlington, ON). NuSerum was from Collaborative Research (Bedford, MA). Anisomycin, arachidonic acid, 2Ј,7Ј-bis(carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM), C8-deficient human serum (C8D), purified human C8, glutathione (GSH), N-acetyl cysteine (NAC), and hydrogen peroxide were from Sigma Chemical (St. Louis, MO). Anti-HA antibody (3F10), protease inhibitor cocktail, and FuGENE 6 were from Roche Diagnostics (Laval, Quebec). Antibodies for phospho-p38 and p38, MAP-KAPK-2, and p38 MAP Kinase Assay Kit were from New England BioLabs (Mississauga, Ontario). Anti-phospho-p38 antibody specifically recognizes p38 that is phosphorylated at Thr180 and Tyr182. Anti-phospho-MAPKAPK-2 antibody specifically recognizes MAPKAPK-2 that is phosphorylated at Thr222. Anti-phospho-HSP27 that specifically recognizes HSP27 phosphorylated at Ser 82 was from Santa Cruz (Santa Cruz, CA). PD-169316 was from Calbiochem (La Jolla, CA). Anti-HSP27 antibody was from Upstate (Lake Placid, NY). Reagents for gel electrophoresis were from Bio-Rad (Mississauga, Ontario). HA-tagged TAK1 cDNA [constitutively active mutant (36) ] was a gift from Dr. K. Matsumoto (Nagoya University, Japan). Plasmids encoding wild-type and non-phosphorylatable mutant hamster HSP27 were gifts from Dr. J. Landry (Laval University, Quebec) (10) . Coding regions of these plasmids were subcloned into a Hind III site of pcDNA3.1 (Invitrogen-Life Technologies).
GEC culture and stimulation by complement. Culture, characterization, and stable transfection of rat GEC were described previously (2, 29) . A subclone of GEC, which stably overexpress cPLA 2 (GEC-cPLA2) (16, 29) , was used unless otherwise noted. GEC-Neo is a control GEC clone, which was transfected with vector alone and expresses only a small amount of cPLA 2. GEC-cPLA2 shows augmented response (in cytotoxicity and eicosanoid generation) to complement stimulation, compared with GEC-Neo (16, 29) . Because GEC in vivo express a significant amount of cPLA 2, GEC-cPLA2 better represent GEC in vivo than GEC-Neo (4). Inducible-TAK1 clones were generated using Ecdysone-Inducible Mammalian Expression System (Invitrogen-Life Technologies). First, GEC were stably transfected with the plasmid pVgRXR and selected by zeomycin. Second, HA-TAK1 subcloned into the pIND/Hygro vector was stably transfected and selected by hygromycin. Expression of HA-TAK1 was induced with an insect hormone, ponasterone A (4 M). Rabbit antiserum to GEC (2) was used to activate complement on GEC membranes. Briefly, GEC were incubated with antiserum (5% vol/vol) for 40 min at 22°C. GEC were then incubated with normal human serum (NS; 2.5-5.0% vol/vol), or heat-inactivated (decomplemented) human serum (HIS; 56°C, 30 min, 2.5-5.0% vol/vol) in controls, for the indicated times at 37°C. In some experiments, antibody-sensitized GEC were incubated with C8D (5.0% vol/vol) reconstituted with or without purified human C8 (80 g/ml undiluted serum). We generally used heterologous complement to facilitate studies with complement-deficient sera and to minimize possible signaling via complement-regulatory proteins; however, in previous studies, results of several experiments involving arachidonic acid metabolism were confirmed with homologous (rat) complement (2) . Sublytic concentrations of complement (Յ5% NS) were established previously (2) . Previous studies showed that, in GEC, complement is not activated in the absence of antibody.
Immunoblotting. Immunoblotting was performed as described previously (29) . Cells or glomeruli were lysed in IP buffer [1% Triton X-100, 125 mM NaCl, 10 mM Tris (pH 7.4), 1 mM EDTA, 1 mM EGTA, 2 mM Na3VO4, 10 mM sodium pyrophosphate, 25 mM NaF] containing protease inhibitor cocktail (Roche Diagnostics). After insoluble components were removed by centrifugation (14,000 rpm, 5 min, 4°C), protein concentration of supernatants was quantified using a commercial reagent (Bio-Rad). Equal amounts of protein were separated by 8% SDS-PAGE under reducing conditions. Proteins were electrophoretically transferred to nitrocellulose membrane, blocked with 5% dry milk, and incubated with first antibodies for 16 h at 4°C. After three washes, membranes were incubated with secondary antibodies conjugated with horseradish peroxidase, and horseradish peroxidase activity was detected by enhanced chemiluminescence (Amersham Pharmacia Biotech, Baie d'Urfé, Quebec). p38 kinase assay was performed using p38 MAP Kinase Assay Kit (New England BioLabs) as per manufacturer's instructions. In brief, cells or glomeruli were lysed in 1ϫ lysis buffer and phosphorylated (activated) p38 was immunoprecipitated with a phospho-specific monoclonal antibody. Immunoprecipitates were subjected to kinase assay using GST-ATF-2 as substrate, and ATF-2 phosphorylation was then detected by immunoblotting using anti-phospho-ATF-2 (Thr71) antibody.
Cytotoxicity assay was performed as described previously (2, 30) . BCECF is a small molecule (molecular mass 520.5) that could be loaded into cells as acetoxymethyl ester. It is released into supernatants when cells are injured; thus it could be used as a marker of cell injury (2) . After complement stimulation, amounts of BCECF released into supernatants and associated with cells were quantified using a fluorometer, respectively. Specific release of BCECF into supernatants was calculated to quantify cytotoxicity using the following formula Lactate dehydrogenase (LDH) is an intracellular enzyme that is substantially larger than BCECF. After complement stimulation, LDH activities in supernatants and cell lysates were quantified as described previously (19) . Specific release of LDH was calculated as described previously (19) in an analogous manner to BCECF. We previously employed both BCECF assay and LDH assay to quantify cytotoxicity and obtained parallel results. In general, we use higher concentrations of serum for LDH assay because LDH is substantially larger than BCECF; thus it requires more injury to be released into supernatants.
Quantification of F-actin. Quantification of F-actin was performed as described previously (30) . After stimulation, cells were washed with PBS and fixed with 2% paraformaldehyde and 4% sucrose in PBS for 10 min. After incubation in NH4Cl (50 mM) for 5 min, cells were permeabilized with 0.5% Triton X-100 for 10 min and blocked with 3% BSA in PBS for 30 min. Cells were incubated with TRITC-phalloidin (0.1 g/ml) for 60 min. After three washes with PBS, TRITCphalloidin was extracted with 2 ml of methanol for 30 min with agitation, and cells were further washed with an additional 1 ml of methanol. Fluorescence of the pooled methanol extracts was quantified in a fluorometer (excitation 542 nm/ emission 563 nm). To confirm that there were similar numbers of viable cells in each well, cells were further washed three times with PBS and were incubated with a nucleic acid-binding fluorescent dye, Toto-3 (100 nM, Molecular Probe, Eugene, OR). Cells were scraped with a rubber policeman, and cell suspensions were transferred to test tubes and sonicated. Fluorescence of the samples was quantified in a fluorometer (excitation 642 nm/emission 660 nm), and results of TRITC-phalloidin were normalized to Toto-3 values.
Induction of PHN and treatment with FR-167963. PHN was induced in male Sprague-Dawley rats (150-175 g body wt, Charles River, St. Constant, Quebec) by intravenous injection (400 l/rat) of sheep anti-Fx1A antiserum as described previously (29) . Preparation of anti-Fx1A antiserum was described previously (20) . Rats did not show significant proteinuria up to 7 days after injection. However, significant proteinuria was observed 14 days after injection (ϳ160 mg/ day; normal rats excrete less than 10 mg of protein per day). FR-167963 was suspended in 0.5% methylcellulose solution, and 32 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 were given subcutaneously from day 7 through 14. On day 14, rats were killed after 24-h urine collection in metabolic cages and glomeruli were isolated by differential sieving as described previously (29) .
Quantification of glomerular rat C3 deposition. Quantification of glomerular rat C3 deposition was performed as described previously with a minor modification (17) . Briefly, 4-m cryostat kidney sections were stained with fluoresceinconjugated rabbit anti-rat C3 (Cappel, Scarborough, Ontario). The immunofluorescence images were captured using a Nikon Diaphoto immunofluorescence microscope and a Nikon Coolpix995 digital camera with a fixed exposure time. Images were transferred to the Adobe Photoshop program, and fluorescence intensity of glomeruli was quantified by histogram analysis. At least eight glomeruli were quantified for each group.
Statistics. Data are presented as means Ϯ SE. The tstatistic was used to determine significant differences between two groups. One-way ANOVA was used to determine significant differences among groups. Where significant differences were found, individual comparisons were made between groups using the t-statistic.
RESULTS

Complement activates p38 in GEC.
We and others reported previously that complement C5b-9 activates kinases such as protein kinase C, ERK (3), and JNK (31) in GEC. In the current study, we examined if complement activates another MAPK, p38. When antibody-sensitized GEC were exposed to NS to form complement C5b-9, p38 phosphorylation increased by 2.2 Ϯ 0.5-fold, compared with control (cells exposed to HIS) [ To verify if C5b-9 assembly was actually required for p38 activation, we incubated antibody-treated GEC with C8D, with or without reconstitution with purified C8. C8D without C8 forms C5b-7, which was previously shown to be biologically inactive in GEC (2) . GEC incubated with C8D did not show significant p38 phosphorylation, compared with HIS. However, when C8D was reconstituted with purified C8, phosphorylation of p38 was evident, indicating that formation of C5b-9 is required for p38 activation (Fig. 1C) . Densitometric analysis showed that the relative p38 phosphorylation was HIS: 1.0, C8D: 0.9, C8D ϩ C8: 2.4 (average of 2 experiments; Fig. 1C ).
To assess if complement-mediated p38 activation occurs in vivo, we next studied p38 activation in glomeruli from rats with PHN. PHN was induced by a single injection of anti-Fx1A antiserum (MATERIALS AND METHODS), and glomeruli were isolated 14 days later, when rats developed significant proteinuria (ϳ160 mg/ day, control rat: Ͻ10 mg/day). p38 was activated by approximately sixfold in glomeruli from rats with PHN, compared with control (control 13 Ϯ 1, PHN 80 Ϯ 22, P Ͻ 0.05, n ϭ 3 and 6; Fig. 2A ). Phosphorylation of p38 was also higher in PHN (2.9 Ϯ 0.2-fold), compared with control (control 1 Ϯ 0.1, PHN 2.9 Ϯ 0.2, P Ͻ 0.01, n ϭ 3 and 6; Fig. 2B ). These results indicate that p38 is activated by complement in GEC in vitro and in vivo.
Arachidonic acid contributes to complement-induced p38 activation. We next addressed the mechanisms of complement-induced p38 activation. It was reported previously that complement activates cPLA 2 in a [Ca 2ϩ ] i -and protein kinase C-dependent manner, leading to a liberation of arachidonic acid from the membrane phospholipid pool (16) . We also reported that complement-induced JNK activation was, at least in part, mediated by arachidonic acid release (17) . We first studied if liberation of arachidonic acid contributes to complement-induced p38 activation. GECcPLA 2 were stimulated with antibody and complement, and p38 activation was compared with control GEC, which were transfected with vector only (GECNeo). p38 was activated by complement 1.4 Ϯ 0.1 times in GEC-Neo, whereas the stimulation was 2.0 Ϯ 0.1 times in GEC-cPLA 2 (n ϭ 3, P Ͻ 0.02), suggesting that liberation of arachidonic acid, at least partially, contributes to complement-induced p38 activation (Fig.  3A) . When GEC-Neo were stimulated with exogenous arachidonic acid (30 M), p38 was clearly activated (2.8 Ϯ 0.6-fold of control, P Ͻ 0.05, n ϭ 5), supporting the role of arachidonic acid in p38 activation (Fig. 3B) .
Unstimulated cultured rat GEC express COX-1, whereas COX-2 expression is induced by complement. Arachidonic acid liberated by cPLA 2 is further converted by COX-1 and -2 into biologically active eicosanoids such as PGE 2 , PGF 2␣ , and TXA 2 (29) . These eicosanoids act via respective specific cell-surface receptors in an autocrine fashion and are known to activate p38 in some systems. To study if eicosanoids contribute to complement-induced p38 activation, we stimulated GEC with PGE 2 , PGF 2␣ , and U-46619 (stable analog of TXA 2 ). When individually tested, these three eicosanoids failed to activate p38 consistently.
Only when three eicosanoids were tested simultaneously was there a modest increase in p38 phosphorylation (ϳ20%, not shown). Furthermore, a nonselective COX inhibitor, indomethacin, failed to inhibit complement-induced p38 activation (not shown). Taken together, these results indicate that arachidonic acid contributes to complement-induced p38 activation but not through conversion into COX metabolites. Instead, arachidonic acid itself and/or other mediators stimulated by arachidonic acid, such as reactive oxygen species (ROS) (see Role of ROS in the activation of p38 by complement), may be responsible for p38 activation.
Role of ROS in the activation of p38 by complement. We previously showed that complement stimulates ROS generation in GEC in an NADPH oxidase-dependent manner, which contributes to JNK activation (17) . We also showed that arachidonic acid stimulates ROS generation in GEC (17) . To test whether ROS contribute to complement-mediated p38 activation, we examined complement-mediated p38 activation in GEC treated with anti-oxidants, GSH, and NAC. As shown in Fig. 4 , GSH (10 mM) and NAC (10 mM) completely abolished complement-induced p38 phosphorylation [control 3.7 Ϯ 0.3-fold of HIS, GSH 0.9 Ϯ 0.03-fold of HIS (P Ͻ 0.01 vs. control), NAC 1.0 Ϯ 0.07-fold of HIS (P Ͻ 0.01 vs. control), n ϭ 3]. Thus ROS are likely to be responsible for complement-induced p38 activation. One mechanism of ROS generation might be arachidonic acid released by cPLA 2 (17) .
Impact of p38 activation on GEC function. We next studied the impact of p38 activation on complementmediated GEC injury. We initially hypothesized that p38 activation contributes to complement-mediated cell injury. However, to our surprise, when GEC were pretreated with p38 inhibitors (PD-169316 and FR-167653, 10 M each), complement-induced cytotoxicity quantified by specific BCECF release (see MATERIALS AND METHODS) was significantly increased, compared with vehicle-treated cells [ Fig. 5A : DMSO: NS 2.5 13 Ϯ Fig. 1 . Complement C5b-9 stimulates p38 in glomerular epithelial cells (GEC) in culture. A: GEC-cytosolic phospholipase A2 (cPLA2) (GEC that stably overexpress cPLA2, see MATERIALS AND METHODS) were incubated with anti-GEC antiserum (5% vol/vol, 22°C, 40 min) and normal human serum (NS; 2.5% vol/vol, to assemble C5b-9, 37°C, 40 min) or heat-inactivated serum (HIS; 2.5% vol/vol, control). Anisomycin (1 M) was used as positive control. Top: immunoblot. Bottom: densitometry. *P Ͻ 0.01, **P Ͻ 0.001 vs. HIS; n ϭ 6 for each group. B: GEC-cPLA2 were stimulated as in A, and p38 activity in cell lysates was evaluated as in MATERI-ALS AND METHODS. H2O2 (1 mM) was used as positive control. Top: immunoblot. Bottom: densitometry. ϩP Ͻ 0.01, ϩϩP Ͻ 0.05 vs. HIS; n ϭ 3-4 for each group. C: antibody-sensitized GEC-cPLA2 were incubated with HIS (2.5% vol/vol), human C8-deficient serum (C8DS; 2.5% vol/vol), or C8DS supplemented with recombinant human C8 (80 g/ml in undiluted serum) for 40 min at 37°C. H2O2 (1 mM) was used as positive control. Top: immunoblot. Bottom: densitometry (mean of 2 experiments). We and others previously reported that complement C5b-9 disrupts actin microfilaments in cultured GEC (30, 33) . One possible mechanism for p38-mediated cytoprotection could be via modulation of the actin cytoskeleton. Thus we next studied the impact of FR-167653 on complement-induced actin depolymerization. When GEC-cPLA 2 were incubated with antibody and complement for 3 h, F-actin content decreased by 9 Ϯ 3%. FR-167653 (10 M) significantly augmented the reduction to 18 Ϯ 4% (P Ͻ 0.05, n ϭ 5 each). Thus p38 activation, at least partly, prevents complementinduced actin depolymerization.
To further validate these results, we next generated subclones of GEC that inducibly express a constitutively active mutant of TAK1, a kinase upstream of p38 (MATERIALS AND METHODS). When one such clone (Fig. 6A,  #1 ) was stimulated with an insect hormone, ponasterone A, expression of TAK1 was induced after 2 h, peaking at 6 h. Phosphorylation of p38 was also observed and peaked at 6 h (Fig. 6A) . Ponasterone A has no known impacts on mammalian cells. When this inducible clone was stimulated with ponasterone A for Fig. 2 . p38 is activated in glomeruli from rats with passive Heymann nephritis (PHN). A: PHN was induced by intravenous injection of sheep anti-Fx1A antiserum. On day 14, rats were killed and glomeruli were prepared by differential sieving. Glomerular lysates were analyzed for p38 activity (A) or p38 phosphorylation (B) as in Fig. 1 . Top: immunoblot. Bottom: densitometry. *P Ͻ 0.05, **P Ͻ 0.01 vs. control; n ϭ 3-6 rats for each group. 4 . Complement-mediated p38 activation is dependent on reactive oxygen species. GEC-cPLA2 were stimulated with antibody and complement (NS). Cells were preincubated with glutathione (GSH; 10 mM) or N-acetyl cysteine (NAC; 10 mM) for 30 min before the stimulation. p38 activation was evaluated by immunoblotting for phospho-p38. Top: immunoblot. Bottom: densitometry. *P Ͻ 0.01 vs. control; n ϭ 3 each. 6 h and exposed to antibody and increasing concentrations of complement (NS), complement-mediated cytotoxicity was attenuated, compared with controls (incubated with ethanol in the place of ponasterone A). Conversely, when cells were preincubated with the p38 inhibitor FR-167653 (10 M, without stimulation with ponasterone A), cytotoxicity was augmented, compared with control, consistent with the previous results (Fig.  6B) . Of interest, when cells were stimulated with ponasterone A in the presence of FR-167653, the impact of ponasterone A (TAK1 induction) was neutralized, but cytotoxicity did not reach the level of FR-167653 treatment alone [control 47 Ϯ 1%, ponasterone A 33 Ϯ 3% (P Ͻ 0.02 vs. control), ponasterone A plus FR-167653 43 Ϯ 3%, FR-167653 alone 57 Ϯ 2% (P Ͻ 0.05 vs. control); Fig. 6C ]. These results indicate that the cytoprotective effect of TAK1 induction is, at least in part, mediated by p38 activation. However, there might be additional pathways downstream of TAK1, which contribute to cytoprotection.
Inhibition of p38 activation augments proteinuria in PHN. The above results suggest that p38 activation is cytoprotective for GEC against complement-mediated cell injury in vitro. We next addressed whether p38 activation is also cytoprotective in vivo using the PHN rat model of membranous nephropathy. In PHN, it is known that complement C5b-9 causes GEC injury, which leads to proteinuria (21, 32). As shown in Fig. 2,   p38 was significantly activated in glomeruli from rats with PHN, compared with control rats. We anticipated that if p38 is cytoprotective for GEC, inhibition of p38 would lead to augmented proteinuria in PHN. Thus we examined the impact of a specific p38 inhibitor, FR-167653, on proteinuria. First, to confirm the effect of FR-167653, rats were treated with FR-167653 from day 7 to 14 (MATERIALS AND METHODS) and p38 activity in glomeruli was studied on day 14. In FR-167653-treated rats, p38 activity in glomeruli was markedly inhibited to a level comparable to that of control rats [control Fig. 6 . Induction of constitutively active transforming growth factor-␤-activated kinase 1 (TAK1) ameliorates complement-induced GEC injury. A subclone of GEC that overexpresses TAK1 (constitutively active mutant) in an inducible manner was established as in MATE-RIALS AND METHODS. A: time course of TAK1 induction. GEC were incubated with ponasterone A (pona; 4 M) for the indicated times and cell lysates were analyzed for expression of TAK1 and phosphorylation of p38 by immunoblotting using antibodies for HA (TAK1) and phospho-p38, respectively. In clone #1, induction of TAK1 peaked at 6 h when phosphorylation of p38 was also observed. In clone #3, induction of TAK1 was weak and phosphorylation of p38 was not detected. B: clone #1 was incubated with vehicle (control), ponasterone A (4 M), or FR-167653 (10 M) for 6 h and stimulated with anti-GEC antiserum and NS (or HIS). Complement-mediated cytotoxicity was quantified as in MATERIALS AND METHODS using BCECF release into the medium. *P Ͻ 0.05, **P ϭ 0.07, ***P ϭ 0.06 vs. control; n ϭ 3 each. 13 Ϯ 1, PHN 80 Ϯ 22 (P Ͻ 0.05 vs. control), PHN-FR-167653 12 Ϯ 5 (not significant from control), n ϭ 3-6; Fig. 7A ]. Phosphorylation of p38 was not affected by this inhibitor in a consistent manner, in agreement with a previous report (27) (Fig. 7A) . In rats treated with vehicle, urinary protein excretion on day 14 was 161 Ϯ 33 mg/day (n ϭ 7), significantly higher than normal rats (ϳ10 mg/day). Consistent with the in vitro cytoprotective effect of p38 activation, rats treated with FR-167653 showed augmented proteinuria (288 Ϯ 54 mg/day, P Ͻ 0.05 vs. vehicle, n ϭ 9; Fig. 7B ). To verify whether complement activation was influenced by FR-167653, we quantified C3 deposition in glomeruli (see MATERIALS AND METHODS). Glomerular C3 deposition was 91 Ϯ 4 in rats with PHN and 93 Ϯ 3 in rats with PHN treated with FR-167653. Thus FR-167653 did not affect complement activation in glomeruli. These results support a cytoprotective role for p38 in complementmediated GEC injury in vivo.
HSP27 overexpression protects GEC from injury. The above results indicate cytoprotective effects of the p38 MAPK pathway in GEC. HSP27 is one of the molecules downstream of p38 MAPK. It is known that when the p38 MAPK pathway is activated, MAPKAPK-2 is phosphorylated/activated and in turn phosphorylates HSP27 (5). It was reported previously that in the rat puromycin aminonucleoside (PAN) nephrosis model, glomerular expression and phosphorylation of HSP27 were increased (24) . Moreover, overexpression of HSP27 in mouse podocytes provided protection against PAN (25) . We also demonstrated that glomerular expression of HSP27 is increased by ϳ1.6-fold in rats with PHN, compared with control rats, similar to the increase seen in PAN nephrosis (24) (Fig. 8A) . When treated with FR-167653, glomerular expression of HSP27 showed an upward trend, although the difference was not statistically significant [control 52 Ϯ 2, PHN 84 Ϯ 10 (P Ͻ 0.01 vs. control), FR-167653 117 Ϯ 11 (P Ͻ 0.01 vs. control), n ϭ 5-8 rats; Fig. 8A ]. We also studied phosphorylation of HSP27 using phospho-HSP27-specific antibody. Phosphorylation of HSP27 in glomeruli was significantly increased in PHN (Fig. 8B) . In contrast to protein expression, phosphorylation of HSP27 was markedly inhibited by FR-167653 [control 15 Ϯ 2, PHN 64 Ϯ 11 (P Ͻ 0.01 vs. control), FR-167653 34 Ϯ 11, n ϭ 6 rats each; Fig. 8B ]. These results suggest that glomerular phosphorylation of HSP27 in PHN is, at least in part, mediated by p38 MAPK.
Thus we next studied whether the cytoprotective effect of the p38 MAPK pathway is mediated via MAP-KAPK-2 and HSP27 in rat GEC in culture. To test this hypothesis, we first studied if MAPKAPK-2 is phosphorylated by complement in GEC. When GEC were on day 14, 24-h urine was collected in metabolic cages and urine protein was quantified. **P Ͻ 0.05 vs. vehicle; n ϭ 7 (vehicle), 9 (FR-167653).
exposed to antibody and complement, phosphorylation of p38 was observed for 20-60 min (Fig. 9A) . Phosphorylation of MAPKAPK-2 was observed in a similar time course (Fig. 9A) . We next studied the impact of overexpression of HSP27 on complement-mediated GEC injury. The plasmid encoding the wild-type HSP27 was stably transfected into GEC, and its expression was verified by immunoblotting. Two subclones (HSP27WT1 and 2) that overexpressed the wild-type HSP27 were selected for further study (Fig. 9B) . Control 1 is a subclone of GEC that was transfected with vector alone and control 2 was transfected with the wild-type HSP27 but the expression level was minimal. It should be noted that control cells also expressed HSP27 when the film was exposed longer (Fig. 9B) . When HSP27WT1 and 2 were simulated with antibody and complement, specific LDH release was markedly attenuated, compared with the two control cells [NS 2.5: control 1 30 Ϯ 4%, control 2 24 Ϯ 3%, HSP27WT1 6 Ϯ 1% (P Ͻ 0.001 vs. both controls), HSP27WT2 7 Ϯ 1% (P Ͻ 0.001 vs. both controls), NS 5: control 1 56 Ϯ 8%, control 2 48 Ϯ 5%, HSP27WT1 10 Ϯ 1% (P Ͻ 0.001 vs. both controls), HSP27WT2 16 Ϯ 1% (P Ͻ 0.001 vs. both controls), NS 10: control 1 73 Ϯ 6%, control 2 66 Ϯ 2%, HSP27WT1 25 Ϯ 1% (P Ͻ 0.001 vs. both controls), HSP27WT2 30 Ϯ 1% (P Ͻ 0.001 vs. both controls), n ϭ 6-12; Fig. 9C ]. To study if phosphorylation of HSP27 is important in cytoprotection, we next established subclones of GEC that overexpress a non-phosphorylatable mutant of HSP27. In this mutant, two Ser residues that are known to be phosphorylated by MAP-KAPK-2 are mutated to Ala (10) . Two subclones (HSP27mut1 and 2) were chosen for further studies (Fig. 9B) . Control 3 is a subclone of GEC that was transfected with vector alone, and control 4 was transfected with HSP27mut, but the expression level was minimal. When HSP27mut1 and 2 were stimulated with complement, specific LDH release was slightly attenuated, compared with control cells, but the attenuation was much smaller than in cells overexpressing the wild-type HSP27 [NS 2.5: control 3 25 Ϯ 4%, control 4 29 Ϯ 2%, HSP27mut1 19 Ϯ 2%, HSP27mut2 31 Ϯ 5%, NS 5: control 3 60 Ϯ 3%, control 4 48 Ϯ 2%, HSP27mut1 41 Ϯ 2% (P Ͻ 0.05 vs. control 3), HSP27mut2 48 Ϯ 2%, NS 10: control 3 66 Ϯ 2%, control 4 62 Ϯ 1%, HSP27mut1 53 Ϯ 1% (P Ͻ 0.05 vs. both controls), HSP27mut2 50 Ϯ 3% (P Ͻ 0.05 vs. control 3), n ϭ 4-12; Fig. 9D ]. These results indicate that overexpression of HSP27 induces cytoprotection in GEC and suggest that MAPKAPK-2-mediated phosphorylation of HSP27 is important in this cytoprotection.
DISCUSSION
Complement-mediated GEC injury plays an important role in proteinuria in the rat model of membranous nephropathy. We and others reported previously that sublytic concentration of complement evokes a variety of signaling events in GEC including the activation of the ERK and JNK pathways (3, 17, 31) . The current study demonstrates that p38 MAPK is also activated by complement in GEC in vitro and in vivo. Similar to JNK activation, p38 activation was, at least in part, mediated by arachidonic acid released by cPLA 2 and ROS. The activation of the p38 MAPK pathway was cytoprotective against complement-mediated injury. Fig. 9 . Overexpression of the wild-type HSP27, but not a nonphosphorylatable mutant, protects GEC against complement-mediated cell injury. A: GEC-cPLA2 were stimulated with antibody and complement for the indicated times. Cells lysates were analyzed by immunoblotting for phosphorylation of MAPKAPK-2 and p38. B: subclones of GEC that stably overexpress the wild-type hamster HSP27 (HSP27WT) or a non-phosphorylatable mutant (HSP27mut) were established as in MATERIALS AND METHODS. Expression of HSP27 was verified with immunoblotting. Note that control GEC also express HSP27 when exposed longer. C: GEC clones that do not overexpress HSP27 (cntl 1 and 2) and GEC clones that overexpress the wild-type HSP27 (HSP27WT1 and 2) were sensitized with anti-GEC antiserum and stimulated with increasing concentrations of NS (or HIS) for 40 min. Specific lactate dehydrogenase (LDH) release was quantified as in MATERIALS AND METHODS as marker of complement-mediated cytotoxicity. *P Ͻ 0.001 vs. cntl 1 and 2; n ϭ 6-12 per group. D: GEC clones that do not overexpress HSP27 (cntl 1 and 2) and GEC clones that overexpress a non-phosphorylatable mutant of HSP27 (HSP27mut1 and 2) were stimulated with complement and LDH release was quantified. ϩP Ͻ 0.05 vs. cntl 3. ϩϩP Ͻ 0.05 vs. cntl 4; n ϭ 4-12 per group.
With the use of the p38 inhibitor FR-167653, Wada et al. (35) elegantly demonstrated that inhibition of p38 MAPK ameliorated histological changes and proteinuria in the nephrotoxic serum nephritis model. The same group also demonstrated that FR-167653 ameliorated histological changes and prolonged survival of MRL-Fas lpr mice (6) . The current results would appear to contradict these earlier reports. However, it should be noted that both nephrotoxic serum nephritis and MRL-Fas lpr mice are models in which glomerular infiltration by leukocytes has a major role. In contrast, infiltrating leukocytes have a minor or negligible role in PHN (32) . Because p38 inhibition by FR-167653 inhibits production of inflammatory cytokines by monocyte/macrophages (27) , it is highly likely that the effects of FR-167653 observed in nephrotoxic serum nephritis and MRL-Fas lpr mice are mediated by inhibition of monocyte/macrophage activation. In fact, in these models, the amelioration of histological changes and proteinuria was paralleled by decreased expression of MCP-1 and glomerular macrophage/lymphocyte infiltration (6, 35) . It is therefore possible that the cytoprotective role of p38 in GEC was unmasked in PHN because leukocyte activation has little role in this proteinuric model. Recently, Stambe et al. (26) confirmed the protective effect of a p38 inhibitor (NPC-31145) in rat nephrotoxic serum nephritis. In this report, activated (phosphorylated) p38 was clearly localized in infiltrating neutrophils. Of interest, in glomeruli of normal rat and human, p38 was expressed in podocytes (26) . p38 in podocytes was phosphorylated even in the normal kidneys, and phosphorylation was further augmented in nephrotoxic serum nephritis (rat) and postinfectious glomerulonephritis (human) (26) . These results support the role of p38 in normal podocyte function as well as in podocyte injury in glomerular disease. In the current study, although it is not possible to determine the site of p38 activation in vivo directly, it is reasonable to assume that GEC are the main site because in PHN, the injury is limited to this cell type (32) .
To date, four isoforms of p38 MAPK, i.e., p38␣, p38␤, p38␥, and p38␦, have been identified (15) . However, no systematic study has been conducted regarding which isoforms are expressed in glomeruli or in GEC. The anti-p38 antibodies used in the current study as well as in the report by Stambe et el. (26) are specific for the p38␣ isoform, confirming the expression of the p38␣ isoform in GEC. In contrast, p38␤ is highly expressed in the brain and heart and p38␥ is expressed primarily in skeletal muscle (15) ; thus these two isoforms are not likely to be contributing to cytoprotection in GEC. In addition, the inhibitor we used in the current study (FR-167653) does not inhibit p38␥ or p38␦ (28) ; thus the cytoprotective effect we observed is not likely to be mediated by these isoforms. Therefore, it is most likely that the p38␣ isoform is responsible for the cytoprotective effect observed in GEC in the current study.
Recently, the importance of the actin cytoskeleton in the structure and function of GEC has been highlighted (8) . We and others reported that complement induces disruption of the actin cytoskeleton (30, 33) . Thus one possible mechanism of the cytoprotective effects of p38 is via interaction with the actin cytoskeleton. Several cytoskeletal proteins are substrates for the p38 pathway, including the microtubule-associated protein tau, the actin-associated protein HSP27, and the intermediate filament proteins h-caldesmon, vimentin, and keratin polypeptides 8, 18 (15) . Among them, HSP27 has been most extensively studied. HSP27 is phosphorylated by MAPKAPK-2, which is phosphorylated/activated by p38 MAPK (5). Phosphorylated HSP27 affords resistance to cells against an inhibitor of actin polymerization, cytochalasin D, in a p38-dependent manner (5) . Phosphorylation of HSP27 also conferred thermal resistance by interacting with actin filaments (11, 12) . In the kidney, Smoyer et al. (24) demonstrated that glomerular HSP27 was upregulated and phosphorylated in the rat model of PAN nephrosis. Overexpression of the wild-type HSP27 in mouse podocytes (GEC) provided protection against PAN-induced microfilament disruption; however, the role of phosphorylation of HSP27 was not addressed in that study (25) . It was also reported that HSP27 limits injury in ATP-depleted renal epithelial cells by associating with the actin cytoskeleton (34) . In the current study, we demonstrated that MAPKAPK-2 is phosphorylated by complement in a similar time course as p38 (Fig. 9A) . Furthermore, GEC that overexpress the wild-type HSP27 showed increased resistance to complement-mediated cell injury (Fig. 9C) . However, this protective effect was markedly decreased when phosphorylation sites of HSP27 were mutated (Fig. 9D) . Our results are therefore in agreement with previous reports and further demonstrate that phosphorylation of HSP27 is indeed a critical mediator of cytoprotection in GEC. Other cytoskeletal proteins downstream of p38 may also contribute to cytoprotection. Further studies are required to clarify the role of the other cytoskeletal proteins in cytoprotection in GEC.
In summary, p38 MAPK is activated by complement C5b-9 in GEC. Activation of p38 leads to phosphorylation of MAPKAPK-2 and HSP27, which contributes to cytoprotection most likely via interaction with the actin cytoskeleton.
